Your session is about to expire
← Back to Search
Individuals with moderate-to-severe psoriasis for Plaque Psoriasis
Study Summary
This trial aims to test a new medication called bimekizumab for treating moderate-to-severe psoriasis in patients who have not responded well to other treatments. Bimekizumab
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the recruitment for this study still ongoing at present?
"According to details on clinicaltrials.gov, this investigation is actively pursuing volunteers. It was initially made public on March 1st, 2024 and received its most recent update on March 21st, 2024."
What is the overall count of individuals participating in this clinical study?
"Indeed, as per clinicaltrials.gov data, this trial is actively seeking participants. Initially listed on March 1st, 2024 and most recently revised on March 21st, 2024, the study aims to recruit a total of 60 individuals from two distinct sites."
What level of risk do individuals with moderate-to-severe psoriasis pose to others?
"Our team at Power rates the safety of individuals with moderate-to-severe psoriasis as a 3 on our scale. This rating is influenced by the fact that this trial falls under Phase 4, indicating approval for this treatment approach."
Share this study with friends
Copy Link
Messenger